2023-07-03 21:20:34
Epidemiological studies have shown, between 2019 and 2020, that taking the progestins cyproterone (Androcur® and generics), nomegestrol (Lutenyl® and generics) and chlormadinone acetate (Lutéran® and generics) leads to an increased risk of meningioma, which increases with the cumulative dose received. Measures to limit this risk were then put in place and a study was launched to assess whether this risk also existed with other progestins, as a class effect cannot be ruled out. The results of this study have just been communicated.
Other relevant progestins
This study was conducted using data from the National Health Data System (SNDS) in more than 18,000 women operated on for meningioma and more than 90,000 control women between 2009 and 2018. Progesterone, medrogestone, medroxyprogesterone, dydrogesterone and dienogest were assessed, as well as levonorgestrel intrauterine devices (IUDs).
The results of this study showed that the prolonged use of medrogestone (Colprone® 5 mg) or medroxyprogesterone acetate (Depo Provera® 150 mg / 3 ml) is associated with an increased risk of meningioma which increases when the duration of use exceeds 1 year, as is the case with Androcur®, Lutényl® and Lutéran®.
No increased risk with levonorgestrel IUDs
On the other hand, no increased risk of meningioma was found with IUDs containing levonorgestrel 13.5 and 52 mg, nor with progesterone (Utrogestan® and generics) and dydrogesterone (Duphaston®, Climaston®).
Regarding dienogest (Visanne® and generics), additional studies should be considered.
Protective measures will have to be taken regarding medrogestone and medroxyprogesterone.
1688437084
#Progestins #increased #risk #meningioma #list #molecules #concerned #growing